Biogen (NASDAQ:BIIB) Price Target Raised to $193.00

Biogen (NASDAQ:BIIB) had its price objective boosted by Truist Financial from $190.00 to $193.00 in a report published on Monday, Marketbeat.com reports. The brokerage currently has a hold rating on the biotechnology company’s stock.

BIIB has been the topic of several other reports. Piper Sandler upped their target price on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday. Citigroup increased their price objective on Biogen from $180.00 to $185.00 and gave the stock a “neutral” rating in a report on Tuesday, January 27th. Mizuho lifted their target price on shares of Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. TD Cowen increased their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Wedbush lifted their price objective on shares of Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research note on Monday. Thirteen analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. Based on data from MarketBeat, Biogen currently has a consensus rating of “Hold” and an average price target of $206.54.

Biogen Stock Performance

Shares of BIIB opened at $191.20 on Monday. The company has a market capitalization of $28.06 billion, a PE ratio of 21.70, a PEG ratio of 1.50 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company’s 50 day moving average price is $177.65 and its 200 day moving average price is $158.12. Biogen has a 52 week low of $110.04 and a 52 week high of $202.41.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the business posted $3.44 EPS. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

A number of hedge funds have recently bought and sold shares of BIIB. Privium Fund Management B.V. acquired a new position in shares of Biogen during the 2nd quarter worth about $2,666,000. Nordea Investment Management AB increased its position in Biogen by 5.7% in the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after buying an additional 6,811 shares during the period. Convergence Investment Partners LLC acquired a new position in shares of Biogen during the third quarter worth approximately $1,342,000. Pitcairn Co. acquired a new position in shares of Biogen during the second quarter worth approximately $936,000. Finally, Fluent Financial LLC bought a new stake in shares of Biogen in the third quarter valued at approximately $3,578,000. 87.93% of the stock is currently owned by institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.